Early Evidence of Impact of Monovalent Rotavirus Vaccine in Togo

Clin Infect Dis. 2016 May 1:62 Suppl 2:S196-9. doi: 10.1093/cid/civ1182.

Abstract

Togo introduced monovalent rotavirus vaccine starting 19 June 2014. We compared all-cause acute gastroenteritis (AGE) hospitalizations and rotavirus-associated hospitalizations during the prevaccine period (July 2008-June 2014) to 1 year after vaccine introduction (July 2014-June 2015). The proportion of children with AGE who tested positive for rotavirus declined from 53% (645/1223) in prevaccine years to 36% (68/187) in the postvaccine year (P< .01). The decline only occurred in children <1 year of age who were eligible for vaccination and was greatest during the rotavirus season months, supporting that it was associated with vaccine implementation.

Keywords: Togo; impact; monovalent rotavirus vaccine; rotavirus.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acute Disease
  • Child, Preschool
  • Female
  • Gastroenteritis / epidemiology*
  • Gastroenteritis / prevention & control*
  • Gastroenteritis / virology
  • Hospitalization
  • Humans
  • Infant
  • Male
  • Rotavirus / immunology
  • Rotavirus Infections / prevention & control*
  • Rotavirus Infections / virology
  • Rotavirus Vaccines / administration & dosage
  • Rotavirus Vaccines / immunology*
  • Seasons
  • Togo / epidemiology
  • Vaccination / statistics & numerical data*
  • Vaccines, Attenuated / administration & dosage
  • Vaccines, Attenuated / immunology

Substances

  • RIX4414 vaccine
  • Rotavirus Vaccines
  • Vaccines, Attenuated